Buprenorphine Combination Tablet Feasibility - 1

NCT00000298 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Opioid-Related Disorders

Interventions

DRUG: Buprenorphine/naloxone

Sponsor

National Institute on Drug Abuse (NIDA)